LAMATTINA JOHN L 4
4 · LIGAND PHARMACEUTICALS INC · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Ligand (LGND) Director John Lamattina Receives RSU Award
What Happened John L. Lamattina, a director of Ligand Pharmaceuticals, was granted a total of 3,774 restricted stock units (RSUs) on June 5, 2026: 836 RSUs reported as shares acquired and 2,938 RSUs reported as a derivative award. The reported acquisition price for both grants is $0 (these are compensatory awards, not open-market purchases or sales).
Key Details
- Transaction date: 2026-06-05; Form 4 filed: 2026-06-09.
- Reported amounts: 836 RSUs (A) and 2,938 RSUs (A, derivative) — total 3,774 RSUs. Reported price: $0 (grant).
- Vesting: Grants vest on the earlier of (A) the date of the next annual meeting of stockholders or (B) the first anniversary of the grant (see footnotes F1 and F2).
- Shares owned following the transaction: not specified in the provided filing details.
- Filing timeliness: Form 4 dated June 9 reports a June 5 grant; Form 4s are generally required within two business days and this filing appears to meet the typical deadline.
Context These entries reflect director compensation awarded as RSUs rather than purchases or sales. RSU grants are common for board members and represent a contingent right to receive common stock upon vesting; they do not by themselves indicate immediate buying or selling sentiment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-05+836→ 31,560 total - Award
Non-Qualified Stock Option (right to buy)
[F2]2026-06-05+2,938→ 2,938 totalExercise: $237.00Exp: 2036-06-05→ Common Stock (2,938 underlying)
Footnotes (2)
- [F1]Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
- [F2]Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.